How to Negotiate a DSO Offer for Your Dental Practice

Key Takeaways

• Direct DSO offers are often starting points, not true market prices. Sellers who accept the first unsolicited bid can leave meaningful cash, equity, and protections unclaimed.
• Three levers – valuation, deal structure, and employment terms – can be some of the main factors that shape offer quality and deserve careful review before you respond.
• An independent CPA-led EBITDA valuation and a structured 45–60-day competitive bid process can create the strongest negotiating leverage.
• Key contract provisions such as earnout metrics, clinical autonomy protections, non-compete scope, and termination rights should be negotiated in writing before you sign a Letter of Intent (LOI).
• McLerran & Associates has guided owners through practice sales representing about $2 billion in closed transaction volume. Find out what your practice is worth before you respond to any offer.

The Information-Asymmetry Gap in DSO Negotiations

A DSO acquisition team reviews dozens of practices each quarter and understands current EBITDA multiples, common seller concessions, and effective anchoring tactics. EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, and it is a standard way to measure a practice’s true operating profit. Owners who accept the first unsolicited DSO offer can receive less value than owners who run a competitive multi-buyer process. This gap can appear across cash at close, rollover equity percentage, earnout structure, employment compensation, non-compete scope, and clinical autonomy protections.

The Three Levers That Shape a DSO Offer

Every DSO offer turns on three levers, and knowing how each one works can support more confident negotiation.

• Valuation. This is the EBITDA multiple applied to your normalized operating profit. Your position within typical ranges can depend on provider depth, hygiene revenue, payer mix, and lease terms.
• Deal structure. This is how the total price breaks into cash at close, rollover equity (an ownership stake in the DSO you receive instead of cash), and an earnout (contingent payments tied to future performance targets). Only the cash-at-close portion is guaranteed.
• Employment terms. These terms cover your post-close compensation rate, schedule, clinical autonomy, non-compete geography and duration, and what happens to your equity and earnout if the DSO terminates you without cause. They can add to or reduce your realized outcome.

Knowing these three levers is helpful, but you cannot negotiate any of them effectively until you understand your practice’s true market value. That is why the first step in responding to a DSO offer usually involves obtaining an independent valuation.

Step 1: Obtain an Independent, CPA-Led EBITDA Valuation Before You Reply

A “free” valuation from the buyer serves as an opening anchor that frames every later conversation. An independent, diligence-grade EBITDA analysis completed before you respond can give you a defensible view of value that you can use in negotiations.

• Confirm that your advisor identifies every legitimate add-back, such as excess owner compensation, personal vehicle expenses, one-time leasehold improvements, and family payroll.
• Verify that normalized EBITDA reflects market-rate clinical compensation so the figure matches what a buyer will actually underwrite.
• Ask whether the valuation will stand up to a buyer’s quality-of-earnings review, which is the formal audit buyers use to verify profitability.
• Request a side-by-side comparison of your value in both the DSO market and the private doctor-to-doctor market so you see your full range of options.

Red flags: A valuation delivered in less than a week without access to your practice management software, a number expressed only as a percentage of collections instead of a multiple of EBITDA, or an advisor who also represents buyers.

Step 2: Create Competition with a Structured 45–60-Day Bid Process

A single offer creates no competitive tension. One of the biggest variables that can move a practice toward the high end of EBITDA multiples is whether the sale process attracts multiple qualified buyers. McLerran & Associates typically runs a structured, auction-style process over 45–60 days, soliciting offers from a vetted pool of buyers while screening out weaker DSOs before they reach the table.

A structured competitive process usually follows a clear sequence designed to build leverage at each stage:

• First, confirm that your advisor contacts both strategic acquirers (DSOs adding to existing infrastructure) and financial buyers (private equity-backed platforms) so you reach the full market.
• Before sharing any financials, ensure that non-disclosure agreements are fully executed to protect confidentiality.
• Require that all initial offers arrive at the same time so no buyer knows what others have bid, which helps create genuine competitive tension.
• After initial offers, narrow the field to the top 2 or 3 finalists before allowing management presentations or site visits, which protects your time and keeps pressure on leading bidders.

Red flags: An advisor who contacts only one or two DSOs, a buyer who imposes a 48-hour LOI deadline that discourages second opinions or a competitive process, or any advisor who works both sides of the transaction.

Step 3: Negotiate Maximum Cash at Close and Practical Earnouts

Cash at close is the only guaranteed part of a DSO offer. Earnouts depend on hitting targets that the buyer will partly control after closing. Negotiating structure before you sign an LOI can be essential, because your leverage usually peaks before exclusivity begins and can decline afterward.

Several coordinated tactics can help you shape a more balanced structure:

• Push for the highest cash-at-close percentage that current market conditions support for your practice profile and location.
• Negotiate pro-rata earnout provisions so a near-miss on an EBITDA target still pays a proportional amount instead of forfeiting the entire earnout.
• Define earnout metrics, measurement periods, accounting rules, and dispute processes in writing before you sign.
• Cap any overhead allocations or integration charges the buyer can apply against your earnout calculation.
• Request a later earnout start date to account for integration disruption during the first months after closing.

Red flags: Earnout targets set above your current trailing EBITDA, vague definitions of “collections” or “production” in the earnout formula, or working capital adjustments – cash, accounts receivable, and supply inventory true-ups – that are not clearly defined.

Step 4: Protect Clinical Autonomy and Staff in Employment Agreements

After closing, you move from owner to employed clinician, and the employment agreement controls your compensation, schedule, and day-to-day clinical independence. Clinical autonomy protections for treatment planning, lab and material selection, and scheduling work best when they appear by name in written agreements, because verbal assurances in an LOI can be overridden later.

Several employment terms often deserve focused attention:

• Confirm that your compensation appears as a percentage of collections, often 30–35% for general dentistry, and compare this figure to your current effective owner distribution rate.
• Negotiate explicit written protections for treatment-planning autonomy, lab and material selection, and scheduling flow for at least the first 12–18 months after closing.
• Secure staff retention commitments in the asset purchase agreement instead of relying on verbal promises.
• Clarify which operational decisions, such as staffing, scheduling systems, and equipment purchases, shift to the DSO and which remain at the practice level.

Red flags: Production quotas tied to compensation or termination rights, approved supplier lists that override your clinical judgment, or employment agreements that fail to distinguish between clinical and administrative responsibilities.

Step 5: Narrow Non-Compete Scope and Add Termination Protections

Buyers often open with non-compete radii of 25 or more miles and durations of 7 or more years, and these terms can frequently be negotiated downward. Enforceability varies by state, so local legal counsel can be crucial.

• Limit the geographic radius to your practice’s actual patient draw area instead of a broad metro region.
• Negotiate the duration down from the buyer’s opening position, with 3 years serving as a more common starting point than 5 or 7.
• Add a termination-without-cause provision that preserves your earnout and rollover equity if the DSO ends your employment.
• Include transitional care carve-outs so you can complete treatment for existing patients within a defined period after departure.
• Confirm that patient non-solicitation and employee non-solicitation provisions appear as separate clauses and that employee non-solicitation is time-limited.

Red flags: Non-competes that cover an entire state, provisions that survive a DSO breach of the employment agreement, or non-solicitation language broad enough to prevent you from hiring staff who leave voluntarily.

Step 6: Model Equity Rollover Like an Investment

Rollover equity, which is the DSO ownership stake you receive instead of cash, can represent a meaningful share of your total deal value. This equity is illiquid until a future recapitalization or sale, typically 5–7 years or longer. It can help to treat it like a venture-style investment rather than guaranteed income.

• Determine whether your equity sits at the joint-venture level (practice-level entity, with distributions but a lower ceiling) or the holding-company level (DSO parent entity, no distributions but higher upside potential).
• Model conservative 3-, 5-, 7-, and 10-year cash-flow forecasts that assume one recapitalization in years 5–7 so you see a range of realistic outcomes.
• Review the DSO’s financial health by asking whether the organization is profitable overall, whether revenue is growing at existing locations, and whether the private equity sponsor is experienced and well-capitalized.
• Confirm vesting schedules and whether double-trigger acceleration, which means full vesting if both a change of control and your termination occur, is available.
• Ask whether your equity position includes any board observer or voting rights, especially if your rollover percentage exceeds 25%.

Single-Offer vs. Competitive-Process Outcomes

Running a competitive process can increase your cash at close, improve earnout terms, and give you leverage on equity structure, which rarely happens with a single direct offer. The table below illustrates how key deal dimensions can differ between accepting a single direct DSO offer and running a structured multi-buyer process.

Dimension	Single Direct Offer	Competitive Multi-Buyer Process	Source
Value vs. going it alone	Buyer-anchored; below competitive outcome	Typically higher headline price; higher net after-tax proceeds	CT Acquisitions
Number of offers received	1	Average of 5+ offers per practice	TUSK Q2 2026 Dental Market Report
Cash at close (typical range)	Buyer-set; often toward lower end of 60–80% range	Competitive tension pushes cash percentage higher within the 60–80% range	Deal Prospectors 2026
Earnout structure	Buyer-drafted; targets and accounting rules favor buyer	Negotiated metrics, pro-rata provisions, capped overhead allocations	Glacier Lake Partners
Equity rollover terms	Standard DSO template; limited negotiation	Competing bids allow negotiation of level (JV vs. HoldCo), vesting, and acceleration	TUSK Q2 2026 Dental Market Report

Red Flags in DSO Contracts

Certain contract provisions can look routine yet materially reduce your realized outcome. The following types of language often deserve careful pushback before you sign.

• “EBITDA maintenance requirement” – a clause that requires you to sustain a specific profit level after closing and can be used to claw back purchase price if performance dips during integration.
• Broad “material adverse change” definitions – language that allows the buyer to renegotiate price during diligence based on minor shifts in collections or patient count.
• Uncapped overhead allocations – provisions that let the DSO charge corporate overhead against your earnout calculation without a defined ceiling.
• Unilateral schedule control – employment language that gives the DSO sole authority over patient volume and appointment quotas, which can directly affect production-based compensation.
• Broad patient record ownership clauses – provisions that assert DSO ownership of clinical charts without clear continuity-of-care protections or post-employment access rights.

The Highest Headline Number Is Not Always the Strongest Outcome

A $10 million offer with a 5-year below-market employment agreement, an aggressive non-compete, and equity in an undercapitalized DSO can produce less long-term value than a lower offer with market-rate compensation, a narrower non-compete, and equity in a well-backed platform with a clear recapitalization plan. A higher purchase price paired with weak employment terms can reduce your total outcome compared with a slightly lower price supported by stronger ongoing compensation.

McLerran & Associates has guided owners through successful practice sales representing about $2 billion in closed transaction volume, with a transaction rate of roughly 85–90%, compared with an industry norm closer to 35–40%. Clients who use a structured sell-side process often see valuations around 30% higher than those achieved by going it alone. That lift usually comes from competitive tension, a defensible EBITDA analysis, and an advisor whose only client in the deal is the seller.

Discuss your potential practice value in the DSO and private-buyer markets before you respond to any direct offer.

Conclusion: Using Professional Representation to Protect Your Legacy

Responding to a DSO offer for your dental practice often starts with a choice between going alone or working with a sell-side advisor whose role is to support your outcome. A direct DSO offer usually serves as a starting point rather than a final market price. An independent, CPA-led EBITDA valuation and a structured 45–60-day competitive bid process among vetted buyers can convert a single offer into real leverage across cash at close, equity structure, earnout terms, clinical autonomy, and staff continuity.

McLerran & Associates is a dental-only sell-side advisor that has evaluated more than 10,000 practices and works both the private-buyer and DSO paths in roughly equal measure, so each client can see a true side-by-side comparison before committing to a direction. The firm focuses on representing sellers rather than buyers.

Talk with McLerran & Associates about your practice and your options before you commit to any DSO path. You can also reach the team at (512) 900-7989 or info@dentaltransitions.com.

Frequently Asked Questions

How do I know if the EBITDA multiple in a DSO offer is fair?

Fairness usually depends on your practice’s specific profile, including size, specialty, provider depth, payer mix, lease terms, and geographic market, rather than a single published number. A diligence-grade EBITDA analysis from an independent CPA-led advisor will normalize your financials, identify legitimate add-backs, and benchmark the resulting multiple against current market activity for comparable practices. Without that baseline, you have limited ability to tell whether the buyer’s offer reflects the market or simply reflects what they believe you will accept. McLerran & Associates prepares this analysis before any buyer sees your financials so the number you present can hold up under scrutiny instead of being renegotiated down during due diligence.

What happens to my rollover equity if the DSO struggles financially after the sale?

Rollover equity in DSO deals is illiquid until a future recapitalization or sale, typically 5–7 years or longer. If the DSO underperforms, sells at a distressed valuation, or faces financial difficulty, the value of that equity can decline significantly or, in severe cases, disappear. This is why McLerran & Associates treats rollover equity as an investment decision as well as a deal term. The firm helps clients review the DSO’s overall profitability, revenue trends at existing locations, management team quality, and the financial strength of the private equity sponsor, and it steers clients toward better-capitalized buyers with stronger track records.

Can I negotiate clinical autonomy protections into a DSO deal, or do I have to accept the buyer’s standard terms?

Clinical autonomy protections are often negotiable, and the LOI stage, before you enter exclusivity with a single buyer, can be the most effective time to secure them. Protections that can be written directly into the employment agreement and management services agreement include treatment-planning autonomy, lab and material selection at the practice level, and scheduling-flow autonomy for a defined period after closing. Written protections usually carry more weight than verbal assurances during early conversations, because post-close integration playbooks can override anything not included in the signed documents. The level of autonomy you can secure also depends on the buyer’s operating style, so references from dentists who have already sold to your finalist buyers can provide useful insight into clinical life after closing.

What is the difference between joint-venture equity and holding-company equity in a DSO deal?

These two structures determine where your rollover equity sits in the DSO’s corporate hierarchy and they carry different risk and return profiles. Joint-venture equity is held at the practice-level or regional entity and typically comes with distributions, which are regular cash payments from practice profits, so it can provide a more predictable income floor but a lower upside because it tracks only your location or region. Holding-company equity is held at the DSO parent entity and usually does not provide distributions, so you receive no cash from that equity until a future liquidity event, but if the DSO grows and recapitalizes at a higher valuation, the upside can be larger. Sellers who do not understand this distinction before comparing offers can be at a disadvantage even when headline multiples look similar. McLerran & Associates models both structures across 3-, 5-, 7-, and 10-year horizons so clients can compare realistic after-tax outcomes.

How long does a properly run DSO sale process take, and what should I expect at each stage?

A well-run sell-side process for a DSO affiliation typically spans about 3–6 months from engagement through closing, although the competitive bid phase, when buyers submit offers, can often be completed in 45–60 days with an experienced advisor. The process usually moves through preparation and valuation, creation of a marketing deck and data room, simultaneous outreach to a vetted buyer pool, collection and ranking of initial offers, management presentations with the top 2 or 3 finalists, LOI negotiation, exclusivity, due diligence, and closing. Delays most often occur during due diligence when a weak or incomplete EBITDA analysis gets challenged by the buyer’s quality-of-earnings team and the deal is renegotiated downward. McLerran & Associates addresses this by completing diligence-grade financial work before the practice goes to market so the agreed value has a stronger chance of holding through closing.